Response to "Lorlatinib Exposed: A Far from Optimal Dose"

Clin Pharmacol Ther. 2022 Jun;111(6):1197-1198. doi: 10.1002/cpt.2580. Epub 2022 Mar 31.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aminopyridines* / adverse effects
  • Humans
  • Lactams
  • Lactams, Macrocyclic
  • Pyrazoles*

Substances

  • Aminopyridines
  • Lactams
  • Lactams, Macrocyclic
  • Pyrazoles
  • lorlatinib